Necrosis

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Retrieved on: 
金曜日, 5月 10, 2024
Patient, SOC, CTCAE, Magnetic resonance imaging, Tumor microenvironment, FDA, MRI, Therapy, Lymph, Necrosis, Neoplasm, PCR, Research, Cancer, Intensity, Mortality, NCI, TNBC, Standard of care, Aggression, European, National Cancer Institute, Pharmaceutical industry

The INVINCIBLE-4 Study is an open-label randomized two-cohort phase 2 clinical trial.

Key Points: 
  • The INVINCIBLE-4 Study is an open-label randomized two-cohort phase 2 clinical trial.
  • SAKK shall undertake the trial as the "Legal Sponsor" of the study, with the regulatory agencies in Switzerland and the European Union as described in the study protocol.
  • SAKK will also ensure that all investigators and personnel who participate in the study are informed and trained.
  • Intensity shall fund the study, provide the investigational drug product, and other necessary information to conduct the trial.

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
木曜日, 5月 9, 2024
MIBC, FDA, Cancer, Urology, Fast Track, Necrosis, SPA, Safety, General counsel, Research, Recurrence, Growth, Light, Bladder cancer, Immunogenic cell death, Incidence, Patient, Enrollment, Compass, Macrophage, NMIBC, Neoplasm, Annual general meeting, Damage-associated molecular pattern, ARVO, Pharmaceutical industry

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.

Key Points: 
  • Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024
    BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.
  • “Throughout the first quarter of 2024, the Company made significant progress across our ocular and urologic oncology therapeutic area programs,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.
  • As of March 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $202.9 million.
  • General and administrative expenses include $1.4 million and $1.1 million of stock-based compensation for the three months ended March 31, 2024 and 2023, respectively.

Rakuten Medical's Poster Presentation at AACR 2024 Demonstrates Reduction in Photoimmunotherapy-induced Edema in Mice with COX-2 Inhibition

Retrieved on: 
金曜日, 4月 12, 2024
Ephrin A2, Mouse, Nonsteroidal anti-inflammatory drug, Necrosis, Blood, Poster, Thromboxane A2, Research, Edema, Neutrophil, Light, Patient, Neoplasm, Head, AACR, Meloxicam, SAN, Vaccine

In the study presented in this poster, Rakuten Medical developed a mouse tumor model to assess edema following photoimmunotherapy and evaluated various steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) for edema reduction using the model.

Key Points: 
  • In the study presented in this poster, Rakuten Medical developed a mouse tumor model to assess edema following photoimmunotherapy and evaluated various steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) for edema reduction using the model.
  • It was also confirmed that the reduction in edema with meloxicam was not associated with a loss of therapeutic benefit based on measurement of tumor growth.
  • Control mice did not generate edema, but mice treated with conjugate plus light showed a light-dose dependent increase in edema volume which peaked at 6h post light delivery.
  • The reduction in edema with meloxicam did not have negative impact on tumor growth inhibition.

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
水曜日, 3月 27, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, NMIBC, Research, Melanoma, Growth, Disease, SPA, Incidence, Paratriathlon, Inflammation, Patient, Necrosis, Travel, Light, Aes, American Academy, Cancer, Șaeș, Bladder cancer, Radiation, Eye, Doctor of Philosophy, MIBC, Visual acuity, Neoplasm, ILS, Aura, Safety, Recurrence, AAO, Annual general meeting, Food, Pharmaceutical industry

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
  • The primary endpoint is time to tumor progression when the last patient completes 15 months of follow up.
  • As of December 31, 2023, Aura had cash and cash equivalents and marketable securities totaling $226.2 million.
  • General and administrative expenses include $1.2 million and $1.1 million of stock-based compensation for the three months ended December 31, 2023 and 2022, respectively.

ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses

Retrieved on: 
月曜日, 3月 4, 2024
Health, Infectious Diseases, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pfizer, Shionogi, 1991 World Sportscar Championship, Aes, Rilpivirine, Fungal infection, GSK, CROI, Absorption, ISR, Cabotegravir, Data, Conference, Administration, Safety, Necrosis, CAB, MPH, Medicine, Half-life, Erythema, Plasma, ViiV Healthcare, HIV, Pharmaceutical industry

ViiV Healthcare is conducting a registrational study of CAB-ULA in 2024 to further evaluate its use for the prevention of HIV in adults.

Key Points: 
  • ViiV Healthcare is conducting a registrational study of CAB-ULA in 2024 to further evaluate its use for the prevention of HIV in adults.
  • Future areas of study will include its potential use in combination with other medicines as a complete, ultra long-acting HIV treatment regimen.
  • ViiV Healthcare is a pioneer and leader in the development of long-acting HIV medicine, having already brought innovations through injectable therapies to the HIV community.
  • Based on these combined findings, ViiV Healthcare is no longer pursuing CAB 200 SC + rHuPH20 for ultra long-acting dosing.

Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Retrieved on: 
火曜日, 1月 2, 2024
Marketing, INN, Risk, Woman, Hypercalcaemia, Menopause, Man, Cancer, Avascular necrosis, Risk management, Anatomy, Female, IIA, Osteitis, Jaw, Osteoclast, CHMP, Fever, Fracture, ATC, Pain, European, Disease, Calcium, Kidney, Paget's disease, Glucocorticoid, Neoplasm, Arthralgia, Hypocalcemia, Patient, Medical Subject Headings, Hip, Trauma, European Commission, Vitamin D, International, Language, Mouth, Select, Medicine, Paget's disease of bone, Allergy, Headache, Ibuprofen, Spine, Myalgia, Committee, Cell, Necrosis, Dietary supplement

Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Cryofocus Medtech Obtains NMPA Approval for the AF Cryoablation System

Retrieved on: 
火曜日, 12月 12, 2023
Necrosis, Hypertension, Republic, Nitrous oxide, Temperature, NMPA, Femoral vein, National Medical Products Administration, Patient, Safety, NOTES, Atrial fibrillation, Pharmaceutical industry

The AF Cryoablation System of Cryofocus Medtech, consisting of the cryoablation equipment, the balloon cryoablation catheter, the disposable intracardiac mapping catheter and the adjustable curved guide catheter, is the first cardiac product that applies cryoballoon with liquid nitrogen as the refrigerant for the treatment of drug-refractory recurrent symptomatic paroxysmal atrial fibrillation.

Key Points: 
  • The AF Cryoablation System of Cryofocus Medtech, consisting of the cryoablation equipment, the balloon cryoablation catheter, the disposable intracardiac mapping catheter and the adjustable curved guide catheter, is the first cardiac product that applies cryoballoon with liquid nitrogen as the refrigerant for the treatment of drug-refractory recurrent symptomatic paroxysmal atrial fibrillation.
  • The approval of the AF Cryoablation System in China markets marks an important milestone in the business development of Cryofocus Medtech in vascular interventional cryotherapy.
  • Meanwhile, the Company's Asthma Cryoablation System and COPD Cryospray System entered into the confirmatory clinical trial phase in March 2023.
  • In addition, as of June 30, 2023, Cryofocus Medtech submitted the registration application for the Cryoadhesion System, and it is expected to obtain approval from the NMPA for the product in the first quarter of 2024.

Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy

Retrieved on: 
月曜日, 12月 18, 2023
Necrosis, Risk, Infection, Human, Inflammatory bowel disease, DRS, Disease, SRA, Harvard Apparatus, Colectomy, Cancer, Abdomen, University, UPMC, OTCQB, Regenerative medicine, Diverticulitis, Patient

Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a center of the University of Pittsburgh and UPMC focused on developing regenerative therapies to address organ and tissue failure.

Key Points: 
  • Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a center of the University of Pittsburgh and UPMC focused on developing regenerative therapies to address organ and tissue failure.
  • The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to repair the colon following colon resection in a rodent model of colectomy.
  • Developing a product to repair and/or regenerate the colon following colectomy will expand our pipeline and further our product portfolio for repairing and regenerating tubular organs within the gastrointestinal tract”, commented Jerry He, Harvard Apparatus Regenerative Technology 's Chief Executive Officer.
  • “The program is designed to test several versions of our cell-based scaffold technology to repair tubular organs in the digestive system.

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

Retrieved on: 
水曜日, 12月 6, 2023
Necrosis, Pyroptosis, Cholesterol, Artery, Inflammasome, Plasma, ASC, AIM2, Therapy, Inflammation, Stroke, Lipid, Animal, Patient, Plaque, Pharmaceutical industry

The study published in Diabetes demonstrates that AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.

Key Points: 
  • The study published in Diabetes demonstrates that AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which inhibits multiple inflammasome pathways (including NLRP3 and AIM2) to attenuate initiation and perpetuation of damaging inflammation that is pathogenic in numerous diseases.
  • In the paper titled, “Hematopoietic NLRP3 and AIM2 inflammasomes promote diabetes-accelerated atherosclerosis, but increased necrosis is independent of pyroptosis,” the authors studied mouse models of type 1 diabetes and atherosclerosis.
  • Results are consistent with other animal model studies showing deficiencies in essential inflammasome components, such as NLRP3, AIM2, ASC, and caspase-1, appear to protect against atherosclerosis.

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Retrieved on: 
金曜日, 12月 8, 2023
Woman, Safety, Therapy, Ottawa Hospital Research Institute, Intensity, Podium, Breast cancer, Fatigue, Patient, Gene expression profiling, Necrosis, The Ottawa Hospital, T helper cell, Immunotherapy, Breast, CD4, Gene expression, Biomarker, Mastectomy, MD, Nausea, Diagnosis, Cancer, University, Downregulation and upregulation, Neoplasm, News, Publication, Injection, NK, Vaccine, Medical imaging

"A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.

Key Points: 
  • "A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.
  • A functional pathway enrichment analysis was conducted and confirmed positive changes in T-cell activation, lymphocyte activation and inflammatory response.
  • Over 95% of treatment-emergent adverse events (TEAEs) were low grade 1 or 2 primarily localized pain, fatigue, and nausea.
  • We see the potential opportunity for our technology and drug products in both the metastatic and presurgical settings for many types of cancers."